(Q35782919)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15161438%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

review article

1 reference

title

Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15161438%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

main subject

acute myeloid leukemia

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15161438%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Gianpietro Semenzato

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15161438%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 June 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15161438%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15161438%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15161438%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15161438%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

387-400

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15161438%20AND%20SRC:MED&resulttype=core&format=json

Stem cells, cancer, and cancer stem cells

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Genetics of myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Molecular genetics of human leukemias: new insights into therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Tyrosine kinase fusion genes in chronic myeloproliferative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

An overview of translocation-related oncogenesis in the chronic myeloid leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

New mechanisms of AML1 gene alteration in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

All-trans-retinoic acid in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Acute promyelocytic leukemia: evolving therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Cancer epigenetics and methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Mammalian Trithorax and polycomb-group homologues are antagonistic regulators of homeotic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Epigenetic cancer therapies: DNA methyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Relevance of DNA methylation in the management of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Cytokine control of developmental programs in normal hematopoiesis and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Hematopoietic cytokines, transcription factors and lineage commitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

JAKs, STATs and Src kinases in hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Targeted therapies in myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Receptor tyrosine kinases in normal and malignant haematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

FMS mutations in myelodysplastic, leukemic, and normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.387

21 January 2018

Identifiers

DOI

10.1586/14737140.4.3.387

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15161438%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference